FAQ
Frequently asked questions.
Short answers about what an analysis produces, what it cannot do yet, and how a project starts.
What does an analysis produce?
A report with response-associated profiles, mechanistic hypotheses or population estimates, figures, robustness checks and an explicit list of limits and next validations. See the example report on synthetic data.
What can it not do yet?
It does not diagnose, predict an individual patient’s response or recommend a treatment or a dose. Results are research hypotheses until they are independently validated.
Which data do you need?
Usually bulk RNA-seq with treatment and response annotations, or public cohorts. Pseudonymised data only. Details are on the Method & data page.
How long does a project take?
Turnaround depends on the data and the question. It is agreed in writing during scoping, before any analysis starts.
How much does it cost?
Pricing is project-based and set in the pilot proposal, together with scope, deliverables and acceptance criteria.
Who owns the results?
Ownership and use of results are defined in the contract. Your data are used only for the agreed project.
Is Recanthia a diagnostic test?
No. Recanthia currently offers research services. A clinical application would require dedicated validation and regulatory steps.
I am a patient — can you help me?
We cannot give medical advice or analyse individual patient data. Please talk to your care team.
When will services be available?
B2B research services are planned for launch in 2027. We already welcome discussions with potential pilot partners.